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ABSTRACT
To study whether treatment with the beta-blocker atenolol (AT) attenuates intestinal
dysfunction caused by ischemia (I) and reperfusion (R), rats were treated with AT (1.5
mg · kg1, intravenously) or saline solution (SS) prior to I (60 minutes), which was
produced by occlusion of the superior mesenteric artery, and/or R (120 minutes). After I
or I/R, 2-cm jejunal segments were mounted in an organ bath to study neurogenic
contractions stimulated by electrical pulses or KCl using a digital recording system. Thin
jejunal slices were stained with hematoxylin and eosin for optical microscopy analysis.
Compared to the sham group, jejunal contractions were similar in the I  AT and the I/R
 AT groups, but reduced in the I  SS and the I/R  SS groups. The jejunal enteric
nerves were damaged in the I  SS and the I/R  SS groups, but not in the I  AT and
the I/R  AT. These results suggest that AT may attenuate intestinal dysfunction caused
by I and I/R.
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sIntestinal ischemia (I) and reperfusion (R) injuries occurin a variety of surgical practices, such as transplantation,
as well as in critical illness, such as neonatal necrotizing
enterocolitis.1 I and R (IR) can lead to hypovolemia,
hypotension, hypoxia, and sepsis1–3 that dramatically com-
romise motor and secretory intestinal functions owing to
ellular lesions caused by deprivation of oxygen and nutri-
nts.1,2 In addition, vessels that suffer R after I can also
suffer cellular lesions and death due to lipid peroxidation of
cell membranes caused by accumulation of free oxygen
radicals and other cytotoxic substances.2,3 The morphologic
nd functional injuries after I and R remain major chal-
enges facing patients undergoing transplantation or major
urgery.
The motor functions of the mammalian intestine are
egulated by several excitatory and inhibitory transmitters
hat are released from enteric nerves, including acetylcho-
ine, adenosine 5=-triphosphate (ATP), nitric oxide (NO),
europeptides, and others.4 The actions of these transmit-
ters depend highly on the integrity of the enteric nerves.5
However, intestinal motor activity is severely compromised
in IR, mainly owing to a loss of structural and functional
integrity of the enteric nerves.5,6
Several drugs have been proposed to attenuate or pre-
vent the structural and functional lesions caused by I and
R.7–12 Previous studies from our group showed that
tenolol (AT), a beta-blocker used to treat cardiovascular
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its.13 However, the exact mechanisms are unknown. In the
resent work we studied the effects of treatment with the
eta-blocker AT on the motility and histology of rat jejunal
egments undergoing intestinal I and R.
MATERIALS AND METHODS
Male Wistar EPM-1 rats (270–300 g) anesthetized with ketamine
(60 mg/kg) and xylazine (40 mg/kg) intravenously underwent
occlusion of the superior mesenteric artery with the use of a
metallic clip for 60 minutes (I) followed by blood recirculation (R)
for 120 minutes following removal of the clip. Twelve rats under-
went only I (I group) and 12 I plus R (IR group), in contrast to a
sham group (n  6).
Among the I group, 6 hosts were treated with 0.9% saline
solution (SS) and 6 with AT (1.5 mg/kg) injected into the femoral
vein 5 minutes before I. In the IR group, 6 rats were treated with
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minute before I, 5 minutes before R, and 55 minutes after R.
After I or IR, the rats were killed to isolate jejunal segments (2
cm) that were washed, cleared of surrounding tissues, and mounted
under 1 g tension at 37°C in an organ bath containing 10 mL
aerated nutrient solution at pH 7.4: NaCl 138, KCl 5.7, CaCl2 1.8,
aH2PO4 0.36, NaHCO3 15, and dextrose 5.5 mmol/L. We studied
neurogenic contractions induced by electrical field stimulation
(EFS) or by the depolarizing agent KCl (70 mmol/L) with the use
of a digital recording system.6–8 EFS (5 and 30 Hz, 1 ms duration,
60 V) was performed by means of platinum electrodes connected to
S88 an electrical stimulator (Grass, USA).6–8
Responses to EFS and KCl were recorded by force-displacement
transducers connected via a bridge amplifier to an analog/digital
recording system (AD Instruments, USA). Data on contractile
responses were subjected to statistical analysis using 1-way analysis
of variance and Student t test.7,8
Fig 1. Typical records of neu-
rogenic contractions induced
by electrical field stimulation (5
and 30 Hz) or KCl (70 mmol/L) in
jejunal segments of rats treated
with AT or SS and submitted to
I or IR. *Statistically different
than I  SS (P  .05; n  6);
#Statistically different than IR 
SS (P  .05; n  6). AT,
atenolol; SS, saline solution; I,
ischemia; R, reperfusion.We also performed histologic analyses of jejunal pieces embed-ded in paraffin, cut into thin slices, and stained with hematoxylin
and eosin for optical microscopy.
Table 1. Values of Amplitude of Neurogenic Contractions
(Expressed in Grams of Tension) Induced by EFS (5 and 30 Hz)
or KCl (70 mmol/L) in Jejunae of Rats Treated with AT or SS
and Submitted to Intestinal I or IR
Group 5 Hz 30 Hz KCl
Sham 1.43  0.12 2.15  0.19 2.25  0.18
 SS 0.18  0.04a 0.28  0.05a 0.41  0.10a
I  AT 0.45  0.10b 0.79  0.15b 0.98  0.14b
I/R  SS 0.18  0.06 0.45  0.10 0.61  0.17
/R  AT 0.98  0.06c 1.15  0.31c 1.57  0.31c
Data correspond to mean  SEM (n  6).
aStatistically different from Sham (P  .05).
bStatistically different from I  SS (P  .05).
cStatistically different from IR  SS (P  .05).
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Figure 1 shows that EFS (5 and 30 Hz) and KCl (70
mol/L) produced contractile responses in all jejunal seg-
ents: Sham, I  SS, I  AT, IR  SS, and IR  AT.
However, the amplitude of these contractions was similar in
I  AT and IR  AT groups, but reduced in I  SS and
/R  SS groups compared with the Sham group (Fig 1;
able 1).
Histological analysis showed a loss of structural integrity
f enteric nerves in the jejunal segments of I/R  SS
Figure 2-B), but not in the I/R  AT group (Figure 2-C).
DISCUSSION
The present work showed the motility stimulated by trans-
mitters released by and the amount of enteric nerves to be
significantly reduced among jejunal segments of rats under-
going intestinal I and IR. However, these dysfunctions were
diminished among hosts treated with AT. These results
suggested that the beta-blocker AT attenuated or prevented
enteric motor and neural dysfunctions caused by intestinal
I and R.
Earlier studies have shown that carvedilol, a beta-blocker
commonly used to treat cardiovascular diseases, such as
hypertension, prevents lipid peroxidation and depletion of
endogenous antioxidants.9–12,14 For example, Ohlstein et
al9 observed that carvedilol (0.1–10 mol/L) attenuated
xygen free radical–initiated lipid peroxidation and inhib-
ted vascular smooth muscle mitogenesis induced by a
ariety of growth factors. More recently, Oliveira et al15
reported that carvedilol inhibited mitochondrial permeabil-
ity transition related to organelle dysfunction in ischemic
conditions, which can ultimately lead to cell death. It is
possible that these molecular mechanisms may be involved
in the protective effects of AT against cellular lesions in the
intestine caused by I and R.
Ignarro6 suggested that the blood pressure–lowering
ffects of nebivolol, a highly selective 1-adrenergic recep-
Fig 2. Histologic aspects of jejunae of sham rat (A) (without isc
atenolol (C) and submitted to intestinal ischemia and/or reperfus
(MI), and enteric nerves (arrows). (Hematoxylin and eosin methoor blocker, were at least partially due to direct vasodilata-ion as a result of NO release from endothelial cells.16–20
The inhibition of -adrenoceptors with nebivolol increases
NO synthase (NOS) activation and reduces NO scavenging
of radical superoxide anions by redirecting deranged NOS
activity from superoxide to NO production. Besides,
nebivolol appeared to possess a complementary antioxidant
activity.16,17,19,20 Maffei et al.21 demonstrated that nebivolol
nduces NO production via activation of 3-adrenoceptors.
Accumulated evidence implicates cross-talk between
-adrenoceptors and adenosine receptors22–24 to promote
cardioprotection22,24 and other cytoprotective effects.23 In-
terfering with those receptors activates or inhibits the
adenosine receptors to promote cytoprotection.
Studying ischemia and reperfusion in rabbits Taha et al12
showed that AT (2.5 mg/kg) improved jejunal function and
morphology in similar conditions as those in the present
study. The functional responses of the rabbit jejunum after
ischemia were similar to control samples (without isch-
emia). The same affect was noted when reperfusion was
performed after AT treatment leading them to conclude
that AT treatment produced cytoprotection because it
improved function and morphology.
In conclusion, treatment with AT attenuated the motor
and neural dysfunctions in rat small bowel caused by I
and R.
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